IXICO launches latest version of AI neuroimaging platform

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics company, has released the tenth version of its proprietary IXI platform, bringing improvements to processing speed, data capacity and image analysis precision. The London-based group uses artificial intelligence to help pharmaceutical companies develop drugs for neurological disorders, including Alzheimer's, Parkinson's and Huntington's disease.